Literature DB >> 10787034

Degeneration of the cerebellar dentate nucleus in corticobasal degeneration: neuropathological and morphometric investigations.

M Su1, Y Yoshida, Y Hirata, Y Satoh, K Nagata.   

Abstract

To resolve the controversy regarding the involvement of the dentate nucleus in corticobasal degeneration (CBD), an entire profile of the dentate nucleus was exposed in a sagittal plane and divided into four fields, and the number of neurons in each filed was counted separately using a computer-assisted analyzer in five cases of CBD and compared to those from seven age-matched controls. The size of the nucleus and the number of neurons were significantly reduced in all five cases of CBD. The neuronal loss had a definite regional predilection, more severe in the caudolateral neodentatum than in the rostromedial palaeodentatum, and was accompanied by grumose degeneration and astrogliosis which paralleled the severity of the neuronal loss. Thus, the dentate nucleus appears to be a cardinal target in CBD.

Entities:  

Mesh:

Year:  2000        PMID: 10787034     DOI: 10.1007/s004010051137

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  3 in total

1.  MR imaging presentation of intracranial disease associated with Langerhans cell histiocytosis.

Authors:  Daniela Prayer; Nicole Grois; Helmut Prosch; Helmut Gadner; Anthony J Barkovich
Journal:  AJNR Am J Neuroradiol       Date:  2004-05       Impact factor: 3.825

2.  Long-term MR imaging course of neurodegenerative Langerhans cell histiocytosis.

Authors:  H Prosch; N Grois; M Wnorowski; M Steiner; D Prayer
Journal:  AJNR Am J Neuroradiol       Date:  2007 Jun-Jul       Impact factor: 3.825

3.  Cerebellar ataxia in patients with mitochondrial DNA disease: a molecular clinicopathological study.

Authors:  Nichola Zoe Lax; Philippa Denis Hepplewhite; Amy Katherine Reeve; Victoria Nesbitt; Robert McFarland; Evelyn Jaros; Robert William Taylor; Douglass Matthew Turnbull
Journal:  J Neuropathol Exp Neurol       Date:  2012-02       Impact factor: 3.685

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.